A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

A Randomized, Balanced, Phase 1/2A, Multiple-dose, Open-label, Two-treatment, Two-period, Two-sequence, Crossover, Relative Bioavailability Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

The goal of this clinical trial is to assess the safety and effects of a crystallized form of lithium, AL001, when compared to commonly used lithium carbonate in individuals diagnosed with bipolar I disorder. The main questions this study aims to answer are:

• How safe is AL001 when compared to lithium carbonate?
• How is AL001 broken down in the brain and body compared to lithium carbonate?

Participants will be asked to:

• Take both the study drug (AL001) and lithium carbonate each for a period of 14 days.
• Stay overnight at MGH's research unit for two separate 2-week periods.
• Participate in two separate 24 hour periods of multiple MRIs and blood draws.

Study Overview

• Status: Recruiting
• Conditions: Bipolar I Disorder
• Intervention / Treatment: Drug: AL001; Drug: Lithium carbonate

Detailed Description

This study is researching the effects of a new type of crystallized lithium, AL001, on it's ability to reach the brain and have an effect in subjects with bipolar I disorder diagnosis. The investigators will be comparing this to a commonly used type of lithium, lithium carbonate. Investigators want to see if the AL001 can have the same or better effect when compared to lithium carbonate. Past research has shown a greater effect within the body with AL001 when compared to commonly used lithium.

This past research suggests that AL001 may be more effective, potentially allowing for lower doses and fewer side effects. If successful, this new form of lithium could offer a new and safe treatment option for psychiatric and neurological disorders.

This study involves two, 2-week long overnight stays at the main campus of Massachusetts General Hospital (MGH). During these stays, participants will receive lithium carbonate for one stay and the AL001 for the other. There are frequent blood draws and brain MRI scans during two periods of the study to look at how the AL001 is broken down in the body and to see how it reaches the brain. This study will compare AL001 to a study reference treatment of lithium carbonate. The majority of the blood draws and MRIs will occur over a 24 hour period during each 2-week long overnight stay at MGH.

• Study Type: Interventional
• Enrollment (Estimated): 20
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Eve del Rio, MD, PhD; Phone Number: (908) 672-6388; Email: eve@riopharma.com

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Recruiting
      • Massachusetts General Hospital
      • Principal Investigator: Ovidiu Andronesi, PhD, MD
      • Contact: Study Coordinator; Phone Number: 617-724-9602; Email: mghlimristudy@mgb.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Subjects with Bipolar I Disorder (BD1) between the age of ≥ 18 and ≤65 years who are in reasonably good physical health, as determined by a DSM-5-TR BD1 diagnosis and the Investigator's review of medical and surgical history, physical examination (including neurological examination), 12-lead ECG, vital signs, and clinical laboratory tests.
2. Assessment of subject's mental health status will be conducted to avoid enrolling subjects who are on the verge of a manic or depressive episode. Affective stability, defined by a Young Mania Rating Scale (YMRS) rating of < 8 and a Hamilton Depression Rating Scale (HDRS-17) rating of < 16 at the Screening visit and on Day -1 (P1). Subsyndromal depression has not significantly worsened in the 4 weeks prior to randomization on Day -1 (P1) so as to avoid enrolling subjects who are on the verge of a full depressive episode. Assessment of subject's suicidal ideation and behavior (SI/B) using the Columbia-Suicide Severity Rating Scale (C-SSRS) will be conducted to avoid enrolling subjects with concerning results, defined as a lifetime history of a suicide attempt, past year level 4 or higher suicidal ideation on the C-SSRS, or past month suicidal ideation of any kind. The "Lifetime/Recent" version will be used at screening and the "Since Last Visit" version will be used subsequently.
3. Clinically acceptable, stably dosed mood stabilizing medication regimen, including treatment regimens with atypical antipsychotic drugs, for > 30 days prior to Screening visit, with no medication changes planned over the entire study period. See Section 6.3 for a list of medications not allowed for mood stabilization purposes. Exceptions to this may be made on a case-by-case basis following agreement by the Investigator and the Sponsor. Also, subjects with untreated BD1 can be enrolled if deemed adequately stable by the Investigator.
4. Able to understand and follow instructions during the study as determined by the Investigator.
5. Willing to follow study procedures.
6. Willing and able to adhere to study restrictions and to be confined at the clinical research center per protocol requirements.
7. Any gender, race, or ethnicity.
8. Able to understand and provide written informed consent.
9. Males (non-vasectomized and vasectomized) must agree to use barrier contraception during the study until after Treatment Period 2 in-clinic follow-up visit on Day 23 (P2).

10. Females must meet one of the following criteria:

    Is of childbearing potential and agrees to use an acceptable contraceptive method. Acceptable contraceptive methods include:

    1. Abstinence from heterosexual intercourse from the Screening visit through to at least 30 days after the last dose of the study drug on Day 14 (P2).

    2. One of the following highly-effective contraceptive methods, used from at least 28 days prior to the Screening visit through to at least 30 days after the last dose of the study drug on Day 14 (P2).

       • i. Systemic contraceptives (combined birth control pills, injectable/implant/insertable hormonal birth control products, or transdermal patch).
       • ii. Intrauterine device (with or without hormones)
       • iii. Male partner vasectomized at least 6 months prior to the Screening visit.

    3. One of the following double-barrier contraceptive methods, used from the Screening visit through to at least 30 days after the last dose of the second study drug on Day 14 (P2):

       • i. Male condom used simultaneously with diaphragm plus spermicide.
       • ii. Male condom used simultaneously with cervical cap plus spermicide.

    Or

    Is of non-childbearing potential, defined as surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation), or is in a postmenopausal state (i.e., at least 1 year without menses prior to the Screening visit).

11. Able to communicate in English, including speaking, reading, and writing.
12. Body mass index (BMI) within 18.0 to 31.0 kg/m2, inclusive, and body weight of at least 50 kg at the time of Screening.
13. ECG recording, after at least 5 minutes of rest in a supine position, without clinically significant abnormalities as determined by the Investigator.

Exclusion Criteria:

1. Clinically significant abnormalities detected by medical history, physical examination, vital sign measurements, ECG findings (including prolonged QT interval), or clinical laboratory findings (as determined by the Investigator) that may affect the safety or successful participation of the subject. Specifically, evidence of clinically significant hematological, renal, endocrine, pulmonary, cardiovascular, dermatologic, muscular, or allergic disease or disorder (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) that may affect the safety or successful participation of the subject.
2. Any history of drug hypersensitivity or asthma (with the exception of childhood asthma), urticaria or other severe allergic diathesis.
3. Presence or history of any disorder other than the diagnosis under study that may prevent the successful completion of the study.
4. Other severe acute, chronic, or historical medical or psychiatric condition or laboratory abnormality or social circumstance that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
5. History of seizure disorder and/or severe head trauma (other than a single childhood febrile seizure).
6. History or presence of gastrointestinal disease including chronic gastritis, peptic ulcers, inflammatory bowel disease, hemorrhagic gastritis, or duodenitis.
7. History or presence of acute or chronic liver disease as determined by the Investigator.
8. Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the study treatments.
9. Any history of frequent headache or migraine.
10. Kidney disease (eGFR < 60 mL/minute/1.73 m2).
11. Uncontrolled tachy/brady arrhythmias, atrial fibrillation, or coronary heart failure.

12. Systemic related exclusions:

    1. Active cancer (except squamous cell and basal skin cancers) requiring chemo- or radiation therapy.
    2. Positive test results for HIV, HBV, or HCV (unless quantitative PCR negative for HCV) at Screening.
    3. Severe hepatic impairment (Child-Pugh Class C).
    4. Uncontrolled hypertension with a sustained blood pressure > 160/100 mmHg at Screening, or at check-in on Day -1 (P1).
    5. Fever (body temperature > 101.4°F [38.5°C]), acute upper respiratory, or any other infections at Screening, or at check-in on Day -1 (P1).
13. Psychiatric or neurological illnesses other than-and not associated with-bipolar I disorder (e.g., bipolar II disorder exclusively, schizophrenia or other psychotic syndromes, Parkinson's disease and related movement disorders, seizure disorder, and myasthenia gravis).
14. Treatment with haloperidol, antipsychotics (except stable regimens), monoamine oxidase inhibitors, neuromuscular blocking agents. Subjects who have ever received chronic immunosuppressant treatment (excluding topical or oral corticosteroids taken 1 year and 5 years before Screening, respectively).
15. Current and during lithium treatment hyponatremia, defined as serum sodium laboratory value outside the standard reference range.

16. The regular and long-term use of any medication, supplement, or OTC medication within 14 days prior to the Screening visit or at least 6 times the respective elimination half-life, whichever is longer, through the completion of the study on Day 42 (P2). EXCEPTIONS to this are as follows:

    1. Hormonal contraceptives for females of childbearing potential.
    2. Acetaminophen (up to 1000 mg TID) at the discretion of the Investigator.
    3. Low-Dose aspirin for cardio protection.
    4. Non-medicated ophthalmic products (for lubrication and comfort).
    5. Clinically acceptable, stably dosed mood stabilizing medication regimen for > 30 days prior to Screening visit, with no medication changes planned over the entire study period. See Section 6.3 for list of medications not allowed for mood stabilization purposes. Exceptions to this may be made on a case-by-case basis following agreement by the Investigator and the Sponsor.
    6. PRN medications needed for treatment of AE's during the study at the joint discretion of the Investigator and the Sponsor, reviewed on a case-by-case basis.
17. Subjects treated with electroconvulsive therapy within 6 months prior to Screening visit.
18. Unwilling to refrain from consumption of poppy seeds or quinine (tonic water) 48 hours prior to check-in on Day -1 (P1) and throughout the course of the study.
19. Aspirin/nasal polyposis/asthma syndrome.
20. Female who is breastfeeding.
21. Female who is pregnant according to the pregnancy test at Screening or on Day -1 (P1); female planning to become pregnant during the study.
22. History of adverse or hypersensitivity reaction to lithium, aspirin, salicylate, L-proline, or any investigational or reference article excipient.

23. Drug/alcohol abuse:

    1. History of drug abuse (barbiturate, amphetamine, benzodiazepine, cocaine, opiates and cannabis) within the last 12 months or a positive urine drug screen at Screening or Day -1 (P1).
    2. Admitted alcohol abuse or history of alcohol use that may interfere with the subject's ability to comply with the protocol requirements or positive ethanol (alcohol) test at Screening or Day -1 (P1).
    3. More than moderate current alcohol consumption. Subjects will be advised to consume no more than 2 units of alcohol per day and completely abstain from 72 hours prior to any study visit (1 unit is equal to approximately 10 g of pure alcohol, [250 mL] of beer [5%], 1 small glass [100 mL] of wine [12%], or 35 mL of spirits [35%]).
24. Demonstrating excess xanthine consumption (e.g., ingests more than 5 cups of coffee or equivalent per day). Also, subject is not willing to refrain from xanthine products for 48 hours prior to check-in on Day -1 (P1) until discharge from Period 2 treatment on Day 15 (P2). The subject is not willing to refrain from grapefruit, pomelo, Seville orange products or juice within 14 days prior to check-in on Day -1 (P1) until discharge from Period 2 treatment on Day 15 (P2). Exceptions may be made on a case-by-case basis following agreement by the Principal Investigator and the Sponsor.
25. Participation in a clinical trial and receipt of an investigational medication within 30 days or 5 half-lives (if known), whichever is greater, prior to the first dose of the current study drug.
26. History of untreated thyroid dysfunction (due to potential lithium drug-disease interaction).
27. Screening MRI-related exclusion criteria: intracranial mass, evidence of other anatomical findings that might affect safety or causes of cognitive/behavioral impairment as assessed by a qualified neurologist. Subjects must not have any implantable medical device (e.g., anueurysm clip, vagus nerve stimulator, cardiac pacemaker) or be reliant on a non-removable medical device (e.g., insulin pump) unless that device is certified as MRI compatible. Known intolerability to MRI neuroimaging procedures.
28. Subjects with any past apparent suicide attempt or suicidal behavior, including those with a lifetime history of suicide attempt(s) or a past year level 4 or higher SI/B (C-SSRS) or past month SI/B (C-SSRS) of any kind.
29. Suspected of having or at risk for Brugada Syndrome.
30. Central nervous system-related exclusions: Any medical condition that in the Investigator's judgement could affect subject safety and scientific integrity of the study, e.g., untreated hypothyroidism (TSH >10 mIU/L) or vitamin B12 deficiency (vitamin B12 <300 pg/mL) which may contribute to cognitive impairment, delirium, dementia and other encephalopathies.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Sequence 1: AL001 then lithium carbonate; Participants take 1050 mg of AL001 TID for 14 days then after a washout period, take 150 mg TID of lithium carbonate for 14 days.	Drug: AL001; Crystallized lithium; Other Names: lithium salicylate/L-proline cocrystal; Drug: Lithium carbonate; Lithium carbonate
Other: Sequence 2: Lithium carbonate then AL001; Participants take 150 mg of lithium carbonate TID for 14 days, then after a washout period, take 1050 mg of AL001 TID for 14 days.	Drug: AL001; Crystallized lithium; Other Names: lithium salicylate/L-proline cocrystal; Drug: Lithium carbonate; Lithium carbonate

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate differences in brain and/or brain structure lithium PK relative to plasma PK for AL001 capsule compared to a lithium carbonate capsule.	Brain (and brain structures)-to-plasma ratios between AL001 and lithium carbonate for steady-state PK measures/ parameters.	From time zero to the end of the 24 hour 3-dose interval at steady state.
To evaluate differences in brain and/or brain structure lithium PK relative to plasma PK for AL001 capsule compared to a lithium carbonate capsule.	Area under the plasma and brain concentration versus time curve (AUC) will be measured.	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Plasma AUCtau ss = Area under the plasma concentration versus time curve from time zero to the end of the 24-hour 3-dose interval at steady-state	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Brain AUCtau ss = Area under the plasma concentration versus time curve from time zero to the end of the 24-hour 3-dose interval at steady-state	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Plasma Cmax ss = Maximum plasma concentration at steady-state	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Brain Cmax ss = Maximum brain concentration at steady-state	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Plasma tmax ss = Time to reach the maximum plasma concentration at steady-state	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Brain tmax ss = Time to reach the maximum brain concentration at steady-state	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Plasma Cmin ss = Minimum plasma concentration at steady-state (if at end-of-24 hour dosing interval: Ctrough)	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Brain Cmin ss = Minimum brain concentration at steady-state (if at end-of-24 hour dosing interval: Ctrough)	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Plasma tmin ss = Time to reach the minimum plasma concentration at steady-state over 24 hours	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Brain tmin ss = Time to reach the minimum brain concentration at steady-state over 24 hours	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Brain/Plasma AUCtau ss ratio = Ratio of brain/plasma areas under the plasma concentration versus time curve from time zero to the end of the 24-hour 3-dose interval at steady-state	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Brain/Plasma Cmax ss ratio = Ratio of brain/plasma minimum concentrations from time zero to the end of the 24-hour 3-dose interval at steady-state.	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Brain/Plasma Cmin ss ratio = Ratio of brain/plasma minimum concentrations from time zero to the end of the 24-hour 3-dose interval at steady-state.	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Plasma apparent oral clearance (CLoral) = Dose24 hours/Plasma AUCtau ss	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Average plasma concentration at steady-state (Css ave plasma) = Plasma 24 h AUCtau ss/24 hours	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Average brain concentration at steady-state (Css ave brain) = Brain 24 h AUCtau ss/24 hours	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Plasma degree of fluctuation at steady-state (FIplasma ss) = Ratio of plasma (Cmax ss - Cmin ss) to Css ave plasma	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Brain degree of fluctuation at steady-state (FIbrain ss) = Ratio of brain 24 h (Cmax ss - Cmin ss) to Css ave brain	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Plasma swing 24 h = [(Cmax ss - Cmin ss)/ Cmin ss ]	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	Brain swing 24 h = [(Cmax ss - Cmin ss)/ Cmin ss ]	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 lithium PK under the conditions of this study	MRT oral doses (0-24h ss) = Mean Residence Time following oral doses at steady-state (0 to tau, end of 24-hour dosing interval)	From time zero to the end of the 24 hour 3-dose interval at steady state.
To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.	Proportion of participants with adverse events and serious adverse events	From enrollment to end of follow-up period at Day 42(P2)
To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.	Proportion of participants with abnormal vital signs	From enrollment to Day 23 (P2)
To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.	Proportion of participants with abnormal values and change from baseline reading for each ECG parameter. Individual parameters including heart rate, PR, QT, QTcF, QRS, and RR intervals will be collected.	From enrollment to Day 23 (P2)
To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.	Proportion of participants with abnormal findings on physical exam.	From enrollment to Day 23 (P2)
To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.	Proportion of participants with abnormal values and changes from baseline for each Safety laboratory test (standard hematology, blood chemistry [clinical chemistry], urinalysis, and pregnancy test [for females of childbearing potential only).	From enrollment to Day 23 (P2)
To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.	Proportion of participants with prevalence of plasma lithium concentrations above 1.2 mEq/L	From enrollment to Day 23 (P2)
To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.	Proportion of participants with prevalence of plasma salicylic acid concentrations above 30 mg/dL	From enrollment to Day 23 (P2)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To characterize AL001 salicylic acid PK under the conditions of this study	Plasma AUCtau ss = Area under the plasma concentration versus time curve from time zero to the end of the 24-hour 3-dose interval at steady-state	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 salicylic acid PK under the conditions of this study	Plasma Cmax ss = Maximum plasma concentration at steady-state	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 salicylic acid PK under the conditions of this study	Plasma tmax ss = Time to reach the maximum plasma concentration at steady-state	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 salicylic acid PK under the conditions of this study	Plasma Cmin ss = Minimum plasma concentration at steady-state (if at end-of-24 hour dosing interval: Ctrough)	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 salicylic acid PK under the conditions of this study	Plasma tmin ss = Time to reach the minimum plasma concentration at steady-state over 24 hours	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 salicylic acid PK under the conditions of this study	Plasma apparent oral clearance (CLoral) = Dose24 hours/Plasma AUCtau ss	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 salicylic acid PK under the conditions of this study	Average plasma concentration at steady-state (Css ave plasma) = Plasma 24 h AUCtau ss/24 hours	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 salicylic acid PK under the conditions of this study	Plasma degree of fluctuation at steady-state (FIplasma ss) = Ratio of plasma (Cmax ss - Cmin ss) to Css ave plasma	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 salicylic acid PK under the conditions of this study	Plasma swing 24 h = [(Cmax ss - Cmin ss)/ Cmin ss ]	From time zero to the end of the 24 hour 3-dose interval at steady state.
To characterize AL001 salicylic acid PK under the conditions of this study	MRT oral doses (0-24h ss) = Mean Residence Time following oral doses at steady-state (0 to tau, end of 24-hour dosing interval)	From time zero to the end of the 24 hour 3-dose interval at steady state.
Exploring Brain Pharmacodynamics using Magnetic Resonance Spectroscopy	Magnetic resonance spectroscopy (MRS) techniques will be applied to explore brain metabolism, including possible metabolic similarities/differences between treatments	From Screening (Day 1) to Day 23 (P2)

Collaborators and Investigators

• Sponsor: Alzamend Neuro, Inc.
• Collaborators: Massachusetts General Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: March 17, 2026
• First Submitted That Met QC Criteria: April 17, 2026
• First Posted (Actual): April 20, 2026

Study Record Updates

• Last Update Posted (Actual): April 20, 2026
• Last Update Submitted That Met QC Criteria: April 17, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Pharmacokinetics; Psychiatry; Neurology
• Additional Relevant MeSH Terms: Inorganic Chemicals; Alkalies; Carbon Compounds, Inorganic; Carbonates; Carbonic Acid; Lithium Compounds; Lithium Carbonate
• Other Study ID Numbers: AL001-BD01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No